Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy.
Botensilimab 是一种 Fc 增强型抗 CTLA-4 抗体，对传统免疫疗法反应不佳的肿瘤有效
期刊:Cancer Discovery
影响因子:33.3
doi:10.1158/2159-8290.CD-24-0190
Chand Dhan, Savitsky David A, Krishnan Shanmugarajan, Mednick Gabriel, Delepine Chloe, Garcia-Broncano Pilar, Soh Kah Teong, Wu Wei, Wilkens Margaret K, Udartseva Olga, Vincent Sylvia, Joshi Bishnu, Keith Justin G, Manrique Mariana, Marques Marilyn, Tanne Antoine, Levey Daniel L, Han Haiyong, Ng Serina, Ridpath Jackson, Huber Olivia, Morin Benjamin, Galand Claire, Bourdelais Sean, Gombos Randi B, Ward Rebecca, Qin Yu, Waight Jeremy D, Costa Matthew R, Sebastian-Yague Alvaro, Rudqvist Nils-Petter, Pupecka-Swider Malgorzata, Venkatraman Vignesh, Slee Andrew, Patel Jaymin M, Grossman Joseph E, Wilson Nicholas S, Von Hoff Daniel D, Stebbing Justin, Curiel Tyler J, Buell Jennifer S, O'Day Steven J, Stein Robert B
